Cetuximab, a chimeric anti-EGFR IgG1 approved by the FDA for HNSCC treatment, binds to EGFR, blocks its signaling pathways, and induces immune-mediated tumor cell death (38). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.